HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II trial of Baker's antifol in metastatic renal cell carcinoma: a Southwest Oncology Group Study.

Abstract
Fifteen patients with metastatic renal cell carcinoma were treated with Baker's antifol at a dose schedule of 250 mg/m2 iv for 3 days every 3 weeks. One objective response was seen, and toxicity was minimal. No usefulness of Baker's antifol in the treatment of metastatic renal cell carcinoma was demonstrated.
AuthorsR M Bukowski, A LoBuglio, J McCracken, R Pugh
JournalCancer treatment reports (Cancer Treat Rep) Vol. 64 Issue 12 Pg. 1387-8 ( 1980) ISSN: 0361-5960 [Print] United States
PMID7471126 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Triazines
  • triazinate
Topics
  • Adenocarcinoma (drug therapy)
  • Adult
  • Aged
  • Diarrhea (chemically induced)
  • Drug Evaluation
  • Female
  • Granulocytes
  • Humans
  • Kidney Neoplasms (drug therapy)
  • Leukocyte Count
  • Male
  • Middle Aged
  • Nausea (chemically induced)
  • Platelet Count
  • Triazines (adverse effects, therapeutic use)
  • Vomiting (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: